University of Bath

Alternative formats

If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

Regulatory Science and Innovation Programme for Europe (ReScIPE): a proposed model

Philip A. Hines[1,2]*, Richard H. Guy [1,4,5], Angela Brand[2,3], Anthony J. Humphreys[1] & Marisa Papaluca-Amati[1]

1   European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

2   United Nations University - Maastricht Economic and Social Research Institute on Innovation & Technology (UNU-MERIT), Maastricht University, Boschstraat, 6211 AX Maastricht, The Netherlands

3   Department of International Health, Faculty of Health, Medicine and Life Sciences (FHLM), Maastricht University, Duboisdomein 30, 6229 GT Maastricht, The Netherlands

4   University of Bath, Centre for Therapeutic Innovation, Department of Pharmacy & Pharmacology, Claverton Down, Bath, BA2 7AY, U.K.

5   University of California - San Francisco (UCSF) - Stanford Center of Excellence in Regulatory Science & Innovation, Department of Bioengineering and Therapeutic Sciences, UCSF, San Francisco, CA 94158, U.S.A.

Table S1: Areas of regulatory science and innovation subjected to horizon-scanning

Science & technology	Regulatory science tools	Health threats	Environment	International regulatory science cooperation
* Major therapeutic areas (oncology, CNS – neurodegeneration, CNS-psychiatry, diabetes, obesity, HIV, vaccines, immunotherapy, etc.) * Gene therapy and regenerative medicine (cells and tissue-based products, novel materials) * Personalised/precision medicine and biomarkers * Methods, technologies, etc. (nanotechnology, 'omics, disease taxonomy, digital health and wearable technology, novel manufacturing and 3-D printing)	* Access pathways (PRIME, adaptive pathways, biosimilars, synergies with HTAs and payers) * Non-clinical methodology (novel models, application of 3Rs in medicines development) * Clinical methodology (modelling and simulation, extrapolation, patient-reported outcomes, new endpoints, Bayesian methods, co-acting medicinal products, novel clinical trials) * Special populations (paediatric, geriatric, pregnancy) * Risk-benefit evaluation * Big data and e-Health (real world evidence, open science, cognitive computing) * Communications (social and behavioural science * Pharmacoepidemiology and pharmacovigilance	* AMR * Emerging threats		